Stock A007570 ILYANG PHARMACEUTICAL CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

News Ilyang Pharmaceutical Co.,Ltd

Equities

A007570

KR7007570005

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 01/07/2024 am IST 		5-day change 1st Jan Change
13,000 KRW +1.72% Intraday chart for Ilyang Pharmaceutical Co.,Ltd +1.09% -16.93%
2023 Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 6, 2023. CI
2023 Ilyang Pharmaceutical Co.,Ltd's Equity Buyback announced on April 6, 2023, has expired with 115,080 shares, representing 0.63% for KRW 1,999.72 million. CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 6, 2023.
CI
Ilyang Pharmaceutical Co.,Ltd's Equity Buyback announced on April 6, 2023, has expired with 115,080 shares, representing 0.63% for KRW 1,999.72 million.
CI
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on April 6, 2023.
CI
Ilyang Pharmaceutical Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Ilyang Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 2,000 million worth of its shares.
CI
Ilyang Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
CI
Tranche Update on Ilyang Pharmaceutical Co.,Ltd's Equity Buyback Plan announced on March 10, 2022.
CI
Ilyang Pharmaceutical Co.,Ltd's Equity Buyback announced on March 10, 2022, has expired with 118,321 shares, representing 0.65% for KRW 2,859.89 million.
CI
Eight South Korean Firms to Donate $2.4 Million Worth of Medicine to Ukraine
MT
Ilyang Pharmaceutical Co.,Ltd announces an Equity Buyback for KRW 3,000 million worth of its shares.
CI
Ilyang Pharmaceutical Co.,Ltd authorizes a Buyback Plan.
CI
Ilyang Pharmaceutical Co.,Ltd(KOSE:A007570) dropped from KOSPI 200 Index
CI
Boryung Pharmaceutical : S.Korea sticks to flu vaccine plan despite safety fears after 25 die
RE
Boryung Pharmaceutical : Number of South Koreans dying after flu shot rises, prompts vaccine worries
RE
Il-Yang Pharmaceutical Signs Licence with Laboratorios Biopas to Export Leukemia Drug Supect to Colombia
CI
Ilyang Pharmaceutical Co., Ltd announced that it has received KRW 30 billion in funding from Hana Daetoo Securities Co., Ltd., Investment Arm, Hanyang Securities Co. Ltd., Investment Arm, Hungkuk Life Insurance Co., Ltd., Korea Securities Finance Corporation, Investment Arm, KTB Investment & Securities Co.,Ltd., and SBI Savings Bank Inc., Investment Arm.
CI
Ilyang Pharmaceutical Co., Ltd announced that it expects to receive KRW 30 billion in funding from Hana Daetoo Securities Co., Ltd., Investment Arm, Hanyang Securities Co. Ltd., Investment Arm, Hungkuk Life Insurance Co., Ltd., Korea Securities Finance Corporation, Investment Arm, KTB Private Equity, and SBI Savings Bank Inc., Investment Arm.
CI
Ilyang Pharmaceutical Co., Ltd's Equity Buyback Plan Extended till September 25, 2022.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A007570 Stock
  4. News Ilyang Pharmaceutical Co.,Ltd